Humoral and cellular immune responses following BNT162b2 XBB.1.5 vaccination
- PMID: 37995739
- DOI: 10.1016/S1473-3099(23)00690-4
Humoral and cellular immune responses following BNT162b2 XBB.1.5 vaccination
Conflict of interest statement
MH, AK, and SP did the contract research (testing of vaccinee sera for neutralising activity against SARS-CoV-2) for Valneva, unrelated to this work. GMNB served as an adviser for Moderna, unrelated to this work. SP served as an adviser for BioNTech, unrelated to this work. AD-J and TW served as an adviser for Pfizer, unrelated to this work. All other authors declare no competing interests. MVS, MH, and RGJ are co-first authors. AD-J and GMNB are co-senior authors.
Similar articles
-
Immune responses following BNT162b2 XBB.1.5 vaccination in patients on haemodialysis in Germany.Lancet Infect Dis. 2024 Mar;24(3):e145-e146. doi: 10.1016/S1473-3099(23)00783-1. Epub 2024 Jan 8. Lancet Infect Dis. 2024. PMID: 38211602 No abstract available.
-
Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden.Lancet Infect Dis. 2024 Feb;24(2):e80-e81. doi: 10.1016/S1473-3099(23)00779-X. Epub 2024 Jan 5. Lancet Infect Dis. 2024. PMID: 38190833 No abstract available.
-
Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination.Allergy. 2022 Aug;77(8):2381-2392. doi: 10.1111/all.15247. Epub 2022 Feb 16. Allergy. 2022. PMID: 35124800 Free PMC article.
-
Enhancement of Humoral and Cellular Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 by a Third Dose of BNT162b2 Vaccine in Japanese Healthcare Workers.J Infect Dis. 2023 Jan 11;227(2):221-225. doi: 10.1093/infdis/jiac344. J Infect Dis. 2023. PMID: 35978486
-
Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19.Cell Rep. 2022 Jan 11;38(2):110235. doi: 10.1016/j.celrep.2021.110235. Epub 2021 Dec 21. Cell Rep. 2022. PMID: 34986327 Free PMC article.
Cited by
-
Neutralizing antibody responses and cellular responses against SARS-CoV-2 Omicron subvariants after mRNA SARS-CoV-2 vaccination in kidney transplant recipients.Sci Rep. 2024 May 28;14(1):12176. doi: 10.1038/s41598-024-63147-z. Sci Rep. 2024. PMID: 38806644 Free PMC article.
-
A recombinant protein vaccine induces protective immunity against SARS-CoV-2 JN.1 and XBB-lineage subvariants.Signal Transduct Target Ther. 2025 Feb 26;10(1):58. doi: 10.1038/s41392-025-02154-6. Signal Transduct Target Ther. 2025. PMID: 40000611 Free PMC article.
-
Evaluating Humoral Immunity Elicited by XBB.1.5 Monovalent COVID-19 Vaccine.Emerg Infect Dis. 2024 Jun;30(6):1282-1283. doi: 10.3201/eid3006.240051. Epub 2024 Apr 26. Emerg Infect Dis. 2024. PMID: 38669121 Free PMC article.
-
An inactivated SARS-CoV-2 vaccine based on a Vero cell culture-adapted high-titer virus confers cross-protection in small animals.Sci Rep. 2024 Jul 24;14(1):17039. doi: 10.1038/s41598-024-67570-0. Sci Rep. 2024. PMID: 39048693 Free PMC article.
-
Omicron XBB.1.5 subvariant causes severe pulmonary disease in K18-hACE-2 mice.Front Microbiol. 2024 Oct 2;15:1466980. doi: 10.3389/fmicb.2024.1466980. eCollection 2024. Front Microbiol. 2024. PMID: 39417078 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources